Soufflé Therapeutics

souffletx.com →

+25%

est. 2Y upside i

HealthcareSeries A

Rank

#1479

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Soufflé Therapeutics offers a high-risk, high-reward equity opportunity.

Last updated: July 19, 2026

Bull (10%)+300%

Breakthrough clinical data and expanded partnerships drive valuation to $1.2B (4x current), validating platform. IPO window opens in 2027-2028.

Base (50%)+70%

Steady preclinical progress and existing collaborations; valuation grows to $500M reflecting milestone achievements and reduced risk.

Bear (40%)-100%

Clinical setbacks or failure in lead asset, compounded by competition from Alnylam; valuation falls below $210M preference stack, wiping out common stock.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

7080%

Total preferred funding of $210M represents 71% of current $296.5M valuation, meaning common stock has low priority in a downside exit.

Dilution Risk

low

With $200M Series A raised in Oct 2025, company has ample runway for 2+ years without need for additional financing.

Secondary Liquidity

none

No secondary market exists for this private stock; exit depends on IPO or acquisition.

Questions to Ask at the Interview

Strategic questions based on Soufflé Therapeutics's data — designed to show you've done your homework.

1
“What is the company's lead indication and timeline to Phase 1 data?”
2
“How does the Bayer collaboration economics work (upfront, milestones, royalties)?”
3
“Given the high preference overhang, what is the expected dilution at next round and how does it impact employee equity?”

Community

Valuation Sentiment

Our model estimates +25% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.